Basic research indicates that DHM is a potential agonist of peroxisome proliferator-activated receptor γ (PPARγ) (112), an important metabolic regulatory factor for targeted treatment of NAFLD (111). The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.